JP2005507872A - ３−置換オキシインドールβ３アゴニスト - Google Patents

３−置換オキシインドールβ３アゴニスト Download PDF

Info

Publication number
JP2005507872A
JP2005507872A JP2003521203A JP2003521203A JP2005507872A JP 2005507872 A JP2005507872 A JP 2005507872A JP 2003521203 A JP2003521203 A JP 2003521203A JP 2003521203 A JP2003521203 A JP 2003521203A JP 2005507872 A JP2005507872 A JP 2005507872A
Authority
JP
Japan
Prior art keywords
alkyl
mmol
amine
mixture
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003521203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507872A5 (cg-RX-API-DMAC7.html
Inventor
ジョリー・アン・バスティアン
ドン・リチャード・フィンリー
ジョン・シャオキアン・ヘ
シンシア・ダーシニ・ジェスダソン
アンドリュー・マイケル・ラッツ
ビンセント・パトリック・ロッコ
ゲルト・リューター
ダニエル・ジョン・ソール
テオ・ショッテン
パトリック・ジャンピエトロ・スピナッツ
フレディー・クレイグ・スティーブンズ
ウィリアム・ジョージ・トランクル
ジョン・アーノルド・ワーナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2005507872A publication Critical patent/JP2005507872A/ja
Publication of JP2005507872A5 publication Critical patent/JP2005507872A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003521203A 2001-08-14 2002-08-06 ３−置換オキシインドールβ３アゴニスト Pending JP2005507872A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31213501P 2001-08-14 2001-08-14
PCT/US2002/021316 WO2003016276A2 (en) 2001-08-14 2002-08-06 3-substituted oxindole beta-3 agonists

Publications (2)

Publication Number Publication Date
JP2005507872A true JP2005507872A (ja) 2005-03-24
JP2005507872A5 JP2005507872A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=23210032

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003521203A Pending JP2005507872A (ja) 2001-08-14 2002-08-06 ３−置換オキシインドールβ３アゴニスト

Country Status (8)

Country Link
US (2) US6911463B2 (cg-RX-API-DMAC7.html)
EP (1) EP1444224B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005507872A (cg-RX-API-DMAC7.html)
AT (1) ATE325119T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002318206A1 (cg-RX-API-DMAC7.html)
DE (1) DE60211199T2 (cg-RX-API-DMAC7.html)
ES (1) ES2262817T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003016276A2 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272749T3 (es) 2001-08-14 2007-05-01 Eli Lilly And Company Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
WO2003044016A1 (en) * 2001-11-20 2003-05-30 Eli Lilly And Company 3-SUBSTITUTED OXINDOLE β3 AGONISTS
JP2005518357A (ja) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ３アドレナリンアゴニスト
WO2003059348A1 (en) 2002-01-11 2003-07-24 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
BRPI0719210A2 (pt) * 2006-10-12 2015-05-05 Xenon Pharmaceuticals Inc Uso de compostos espiro-oxindol como agentes terapêuticos
EP2076514A1 (en) * 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Spiro (furo ý3, 2-c¨pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
JP2010522690A (ja) * 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US8101647B2 (en) * 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102946859B (zh) 2010-02-26 2016-03-02 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB159945A (en) 1919-11-28 1921-02-28 Ernest Henry Jones Removable covers for welding and like furnaces
CH624395A5 (cg-RX-API-DMAC7.html) 1976-01-08 1981-07-31 Ciba Geigy Ag
CA1116598A (en) 1977-07-13 1982-01-19 William T. Comer 3-indolyl-tertiary butylaminopropanols
JPS6010021B2 (ja) * 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
DE3423429A1 (de) 1984-06-26 1986-01-02 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3426419A1 (de) * 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4728651A (en) 1985-10-24 1988-03-01 Hoechst-Roussel Pharmaceuticals Inc. Antihypertensive thieno-isoxazoles and -pyrazoles
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
TW363959B (en) 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
EP0906310A4 (en) 1996-06-07 1999-09-01 Merck & Co Inc OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US5808080A (en) * 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
US6011048A (en) * 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
JP2001509166A (ja) 1997-01-28 2001-07-10 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のためのβ▲下３▼作動薬としてのチアゾールベンゼンスルホンアミド
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003055344A (ja) * 1999-01-29 2003-02-26 Dainippon Pharmaceut Co Ltd ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001036412A1 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
WO2001035947A2 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
US6420365B1 (en) 2000-01-18 2002-07-16 Neurogen Corporation Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
CN1441800A (zh) 2000-07-13 2003-09-10 伊莱利利公司 β3肾上腺素能激动剂
EP1341759B1 (en) * 2000-11-10 2006-06-14 Eli Lilly And Company 3-substituted oxindole beta 3 agonists

Also Published As

Publication number Publication date
ATE325119T1 (de) 2006-06-15
DE60211199D1 (de) 2006-06-08
EP1444224A2 (en) 2004-08-11
AU2002318206A1 (en) 2003-03-03
WO2003016276A2 (en) 2003-02-27
US6911463B2 (en) 2005-06-28
US20050159473A1 (en) 2005-07-21
DE60211199T2 (de) 2007-02-01
EP1444224B1 (en) 2006-05-03
US7087635B2 (en) 2006-08-08
ES2262817T3 (es) 2006-12-01
WO2003016276A3 (en) 2004-05-27
US20040242668A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
JP2005507872A (ja) ３−置換オキシインドールβ３アゴニスト
ES2272749T3 (es) Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2.
CN101341149B (zh) 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
JP5535931B2 (ja) 二環性化合物
JP2005501856A5 (cg-RX-API-DMAC7.html)
EP1254134B1 (fr) Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands pour les recepteurs v1b ou v1b et v1a de l'arginine-vasopressine
KR20030036917A (ko) 치환된 인돌, 이를 함유하는 약제학적 조성물, 및 이의ＰＰＡＲ-γ결합제로서의 용도
CA2421594A1 (en) 3-substituted oxindole beta 3 agonists
FR2804114A1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JPH07504919A (ja) ５−ｈｔ１作動薬としてのインドール誘導体
CN114409656B (zh) Pim激酶抑制剂
FR2805536A1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
CA2716035A1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
JP2001513764A (ja) ５−ｈｔ２ａ拮抗剤としてのオキサゾリジン類
KR20080105092A (ko) 피롤 유도체 또는 그의 염
WO2021107125A1 (ja) リゾホスファチジン酸受容体作動活性を有する化合物およびその医薬用途
KR20040041092A (ko) 우울증 및/또는 불안증의 치료를 위한 ｇａｌ3 수용체길항물질의 용도 및 상기와 같은 방법에 유용한 화합물
KR20080065674A (ko) 신규한 인돌 함유 베타 효능제, 이의 제조 방법 및약제로서의 이의 용도
WO2004009585A2 (fr) Derives d'acyloxypyrrolidine et leur utilisation en tant que ligands des recepteurs v1b et v1a de avp
JPH02250862A (ja) アミノアルコキシフェニル誘導体、その製法およびそれを含有する組成物
TWI454473B (zh) 稠環化合物及其用途
WO2004098610A1 (en) Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands
TW201029996A (en) Heterocyclic compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090714